Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Price

Movement

( )

(20 mins delayed)

52 Week Range

-

 
1 Year Return

 

Telix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $8.61 billion
P/E Ratio 181.74
Dividend Yield 0.00%
Shares Outstanding 334.72 million
Earnings per share 0.145
Dividend per share N/A
Year To Date Return 6.79%
Earnings Yield 0.55%
Franking -
Share Price

Day Change

( )

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

  • Telix Pharmaceuticals Ltd (ASX: TLX)
    Latest News

    A man holds his head in his hands, despairing at the bad result he's reading on his computer.
    Share Fallers

    Why Brambles, Bravura, Pantoro, and Telix shares are sinking today

    These shares are starting the week in the red. But why?

    Read more »

    Shot of a young scientist looking stressed out while working on a computer in a lab.
    Healthcare Shares

    Telix shares crash 8% on US FDA blow

    This high-flying stock has been hit with some bad news.

    Read more »

    A boy is excited because he won the computer game.
    Share Market News

    Telix: A masterclass in what this game is all about

    Today's market darling reminds us why we love to invest. But is it too late?

    Read more »

    Happy man working on his laptop.
    Share Market News

    5 things to watch on the ASX 200 on Thursday

    A decent finish to the week is expected for Aussie investors.

    Read more »

    Man on computer looking at graphs
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Investors were back to the races this hump day...

    Read more »

    Rising share price chart.
    Share Gainers

    Why Orthocell, Paladin Energy, Telix, and Woodside shares are racing higher today

    These shares are having a stronger day than most. But why?

    Read more »

    Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
    Healthcare Shares

    Telix shares rocket 15% on stellar Q1 sales update

    Let's see how the company performed during the three months.

    Read more »

    Smiling man with phone in wheelchair watching stocks and trends on computer
    Share Market News

    5 things to watch on the ASX 200 on Wednesday

    A great session is expected for Aussie investors today.

    Read more »

    A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
    Growth Shares

    Invest $10,000 in these fantastic ASX growth shares

    Analysts believe that these shares could be in the buy zone right now.

    Read more »

    Man presses green buy button and red sell button on a graph.
    Broker Notes

    5 top ASX 200 stocks that brokers rate as buys after the market selloff

    These stocks could be top buys for investors looking to add to their portfolio.

    Read more »

    Happy shareholders clap and smile as they listen to a company earnings report.
    Broker Notes

    3 of the very best ASX shares to buy now

    These shares are highly rated by the team at Bell Potter for a reason.

    Read more »

    Happy man working on his laptop.
    Share Market News

    5 things to watch on the ASX 200 on Monday

    It looks set to be a good start to the week for Aussie investors.

    Read more »

    Frequently Asked Questions

    TLX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Telix Pharmaceuticals Ltd

    Telix Pharmaceuticals Ltd (ASX: TLX) is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic ('theranostic') products using targeted radiation. This process treats cancerous or diseased cells, an alternative approach to many cancer therapies which also attack healthy tissue at the same time.

    Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent Illuccix. It is working to get Illuccix approved for sale in the UK and Europe. 

    The company also has more than 20 clinical trials underway worldwide. Telix's research and development is focused on prostate, renal (kidney), glioblastoma (brain), and hematologic (bone marrow conditioning) cancers, as well as rare diseases. The company is headquartered in Australia with offices in Belgium, Japan, Switzerland, and the United States. 

    TLX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    29 May 2025 $25.47 $-0.81 -3.08% 865,239 $26.50 $26.51 $25.44
    28 May 2025 $26.28 $0.08 0.31% 895,910 $26.46 $26.55 $26.10
    27 May 2025 $26.20 $0.36 1.39% 981,933 $26.09 $26.47 $25.91
    26 May 2025 $25.84 $0.35 1.37% 686,812 $25.46 $25.94 $25.44
    23 May 2025 $25.49 $0.24 0.95% 791,043 $25.55 $25.61 $25.23
    22 May 2025 $25.25 $-0.43 -1.67% 1,316,037 $24.79 $25.53 $24.73
    21 May 2025 $25.68 $0.33 1.30% 855,548 $25.79 $26.20 $25.32
    20 May 2025 $25.35 $-0.39 -1.52% 1,103,065 $26.01 $26.23 $25.25
    19 May 2025 $25.74 $-0.26 -1.00% 933,488 $25.30 $26.21 $25.08
    16 May 2025 $26.00 $0.86 3.42% 946,884 $25.75 $26.25 $25.44
    15 May 2025 $25.14 $-0.42 -1.64% 1,392,590 $25.50 $25.70 $25.13
    14 May 2025 $25.56 $0.20 0.79% 1,934,309 $25.69 $26.52 $25.56
    13 May 2025 $25.36 $0.89 3.64% 2,548,799 $25.90 $26.00 $25.05
    12 May 2025 $24.47 $-2.33 -8.69% 4,082,759 $26.11 $26.34 $24.18
    09 May 2025 $26.80 $0.18 0.68% 1,111,086 $26.88 $27.17 $26.36
    08 May 2025 $26.62 $-0.48 -1.77% 1,835,624 $26.80 $27.58 $26.62
    07 May 2025 $27.10 $-0.94 -3.35% 1,841,789 $27.41 $27.77 $26.87
    06 May 2025 $28.04 $-1.12 -3.84% 1,257,289 $28.76 $29.21 $27.93
    05 May 2025 $29.16 $-0.16 -0.55% 1,205,796 $29.30 $29.64 $29.02
    02 May 2025 $29.32 $1.33 4.75% 2,289,677 $27.69 $29.50 $27.67
    01 May 2025 $27.99 $0.86 3.17% 1,295,208 $27.61 $28.19 $27.30
    30 Apr 2025 $27.13 $0.18 0.67% 992,006 $27.30 $27.48 $26.92
    29 Apr 2025 $26.95 $0.27 1.01% 1,548,203 $26.59 $27.64 $26.45

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    06 Mar 2025 Christian Behrenbruch Expiry 46,558 $1,306,417
    As advised by the company. Lapsed, 3,57,419 Rights
    05 Mar 2025 Tiffany Olson Buy 11,315 $319,422
    On-market trade. Average price
    05 Mar 2025 Marie McDonald Buy 3,719 $100,078
    On-market trade. Average price
    27 Feb 2025 Harry McCann Sell 30,000 $912,900
    On-market trade.
    27 Feb 2025 Christian Behrenbruch Sell 2,000,000 $59,000,000
    Off-market trade.
    26 Jun 2024 Christian Behrenbruch Issued 144,037 $856,158
    As advised by the company. Non - Cash, Black Scholes, 403,977 Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Jann E Skinner Non-Executive Director Jun 2018
    Ms. Skinner has financial acumen, accounting and auditing expertise, with understanding of risk management compliance frameworks and control oversight. Her listed company experience and expertise in capital management and corporate development enable her to challenge management constructively. Ms. Skinner has experience in auditing, accounting and in the insurance industry. She was a partner of PricewaterhouseCoopers for 17 years before retiring in 2004. She has served as a Director of Create Foundation Limited (since June 2004). She previously also served as a Director of HSBC Bank Australia Limited (from April 2017 to April 2023) and as an independent Non-Executive Director of QBE Insurance Group Limited (from October 2014 to May 2024). She is chair of Risk Commitee and member of People, Culture Committee and Disclosure Commitee.
    Ms Marie Elizabeth McDonald Non-Executive Director Mar 2025
    Ms McDonald is a Director of several ASX-listed life science companies including CSL and Nanosonics. She brings experience in financial markets, mergers and acquisitions, regulatory policy, remuneration, risk management and compliance. Ms McDonald practised for 30 years as a commercial lawyer for law firm Ashurst Australia and was previously a long-serving member of the Australia Takeovers Panel.
    Dr Christian Peter Behrenbruch Chief Executive OfficerManaging Director Jan 2017
    Dr. Behrenbruch has more than two decades of radiopharmaceuticals experience and a track record in global healthcare and biotechnology entrepreneurship and technology commercialization. He brings a blend of technical expertise and executive leadership to guide Telix as it enters the next stage of its strategy. Dr. Behrenbruch has a focus on purpose and values-leadership, and is versed in all aspects of running a publicly listed company as both CEO and Director in the U.S. and Australia. Previously, Dr. Behrenbruch served as Chief Executive Officer at Mirada Solutions (now Mirada Medical Limited) (from July 2001 to December 2002), President at CTI Molecular Imaging (now Siemens Healthcare) (from August 2003 to September 2006), Chief Executive Officer at Fibron Technologies, Inc. (from June 2008 to December 2011) and Chief Executive Officer at ImaginAb, Inc. (from October 2007 to February 2015). He served as a Director at Siemens Molecular Imaging Ltd (from May 2005 to September 2006), Momentum Biosciences LLC (from July 2007 to June 2009), Radius Health Ltd (now Adaptix Ltd) (from May 2009 to February 2011). Dr. Behrenbruch was the Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre) (from October 2012 to July 2014). He is member of Disclosure Commitee.
    Dr Mark Alexander Nelson Non-Executive Director Sep 2017
    Dr. Nelson's experience in the investment community, including in life sciences, brings a sound investment perspective to the implementation of Telix's strategy. Dr. Nelson has served as Chairman of the Caledonia Investments Group (since January 2012) and as a Director of The Caledonia Foundation (since August 2002). He previously served as Chief Executive Officer and Co-Chief Investment Officer of the Caledonia Investments Group (from February 1992 to January 2012). Dr. Nelson has served as Chairman of Art Exhibitions Australia (since 2019), Director of the Mindgardens Neuroscience Network (since February 2018), Governor of the Florey Neurosciences Institute (since October 2007), and Director of Kaldor Public Art Projects (since October 2005). He is member of risk committee and People and Culture Committee.
    Ms Tiffany Olson Non-Executive DirectorNon-Executive Chairman Mar 2022
    Ms. Olson brings experience in commercialization and corporate strategy in oncology, including in the radiopharmaceuticals sector, which the Telix Board values as it oversees the implementation of the Company's strategy. Ms. Olson's most recent executive role was with Cardinal Health, the provider of radiopharmaceuticals in the U.S.. As President of Cardinal Health Nuclear & Precision Health Solutions (from July 2013 to October 2021), overseeing Cardinal's radiopharmaceutical manufacturing and nuclear pharmacy network, she led a business transformation that increased market share and profit growth. Prior to Cardinal Health, Ms. Olson served as President of NaviMed (from August 2011 to July 2013), as Vice President Diagnostics at Eli Lilly and Company (from November 2009 to July 2011), and as President and Chief Executive Officer at Roche Diagnostics Corporation (from June 2005 to May 2008). Previously she was a Director at Asuragen, Inc (from August 2016 to March 2021) and at BioTelemetry, Inc. (from February 2019 to February 2021). She currently serves as a Director of Castle Biosciences, Inc. (since April 2021), an Advisory Board member at Langham Logistics (since August 2021), a Director at Education and Research Foundation, Nuclear Medicine & Molecular Imaging (since April 2022), a Partner at Trusted Health Advisors (since August 2023) and Director of MiMedx Group, Inc. (since March 2024). She is member of risk committee and People and Culture Committee.
    Ms Genevieve Ryan Company Secretary Dec 2022
    -
    James Stonecypher Chief Development Officer
    -
    Raphael Ortiz Chief Executive Officer Telix International
    -
    Kevin Richardson Chief Executive Officer Telix Precision Medicine
    -
    Richard Valeix Chief Executive Officer Telix Therapeutics
    -
    Genevieve Ryan Company Secretary
    -
    Darren Smith Group Chief Financial Officer
    -
    Dr. David Cade Group Chief Medical Officer
    -
    Darren Patti Group Chief Operating Officer
    -
    Lena Moran Adams Group General Counsel
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 53,991,544 16.38%
    J P Morgan Nominees Australia Pty Limited 41,431,033 12.57%
    Citicorp Nominees Pty Limited 37,037,359 11.24%
    Elk River Holdings Pty Ltd 22,675,000 6.88%
    Gnosis Verwaltungsgesellschaft Mbh 22,675,000 6.88%
    Grand Decade Developments Limited 10,947,181 3.32%
    BNP Paribas Nominees Pty Ltd 5,668,855 1.72%
    Uv Cap GMBH & CO KG 5,427,233 1.65%
    National Nominees Limited 4,898,643 1.49%
    BNP Paribas Noms Pty Ltd 4,862,009 1.48%
    Man Holdings Pty Ltd 3,228,750 0.98%
    BNP Paribas Nominees Pty Ltd i 3,004,126 0.91%
    BNP Paribas Nominees Pty Ltd ii 2,746,672 0.83%
    The Oncidium Foundation 2,513,616 0.76%
    HSBC Custody Nominees ( Limited A/C 2 2,172,354 0.66%
    Netwealth Investments Limited 2,010,924 0.61%
    Pacific Custodians Pty Limited 1,990,000 0.60%
    BNP Paribas Noms (Nz) Ltd 1,983,417 0.60%
    Yelwac Pty Ltd 1,762,500 0.53%
    Buttonwood Nominees Pty Ltd 1,650,000 0.50%
    HSBC Custody Nominees ( Limited 1,543,217 0.47%

    Profile

    since

    Note